GLSI News and Press, Greenwich LifeSciences Inc. From 03/08/21

GLSI - GME, BILI, JAGX and SOS among midday movers

Gainers: Second Sight Medical Products (EYES) +94%.OpGen (OPGN) +71%.Anchiano Therapeutics (ANCN) +66%.GameStop (GME) +44%.Jaguar Health (JAGX) +35%.Moxian (MOXC) +30%.Koss (KOSS) +30%.Idera Pharmaceuticals (IDRA) +28%.BSQUARE (BSQR) +25%.Greenwich LifeSciences (GLSI) +23%.Losers:&#...

GLSI - Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer

Actively involved in over 200 clinical trials 30 years experience in managing clinical trials and FDA interactions, leveraging biostatistics PhD Founding partner of multiple CROs Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-st...

GLSI - Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal P...

GLSI - Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that two abst...

GLSI - Greenwich LifeSciences Announces Exercise and Closing of Underwriter's Over-Allotment Option

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that the unde...

GLSI - Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that an exclu...

GLSI - Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal P...

GLSI - Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal P...

GLSI - Greenwich LifeSciences' LD Micro Presentation Replay Now Available

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that a replay...

GLSI - Altimmune: AdCOVID's Potential To Prevent Transmission May Be Key To Ending The Pandemic

Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the fundamental picture has improved with more clarity around manufacturing. ALT has ...

Company Name:	Greenwich LifeSciences Inc.
Stock Symbol:	GLSI
Market:	NASDAQ
Website:	greenwichlifesciences.com